<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04030520</url>
  </required_header>
  <id_info>
    <org_study_id>MH114523</org_study_id>
    <secondary_id>R34MH114523</secondary_id>
    <nct_id>NCT04030520</nct_id>
  </id_info>
  <brief_title>Improving Uptake and Adherence to HIV Prevention Services With Pre-exposure Prophylaxis (PrEP), HIV Self- Testing and Adherence Support for Very High Risk HIV-negative Young Women Aged 15-24 in Kampala, Uganda</brief_title>
  <acronym>POPPi</acronym>
  <official_title>Improving Uptake and Adherence to HIV Prevention Services With PrEP, HIV Self- Testing and Adherence Support for Very High Risk HIV-negative Young Women Aged 15-24 in Kampala, Uganda</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MRC/UVRI and LSHTM Uganda Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim is to develop and assess an intervention to enhance initiation and adherence to&#xD;
      PrEP among HIV negative young women of high risk (YWHR). The specific aims are (1) To conduct&#xD;
      formative research to enhance our understanding of the dynamics of the social and sexual&#xD;
      networks, and context of young HIV-uninfected women (aged 15-24) engaged in high risk sexual&#xD;
      behavior in Kampala, Uganda (2) Document barriers and opportunities for PrEP uptake and&#xD;
      adherence as well as repeat HIV testing by self test; (3) To develop and test a socially and&#xD;
      culturally acceptable and feasible prevention intervention on uptake and adherence to PrEP&#xD;
      and HIV self-testing for young women at high risk for HIV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initiation of PrEP</measure>
    <time_frame>12 months</time_frame>
    <description>Initiation of PrEP using the pharmacy records indicating PrEP received by participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to PrEP</measure>
    <time_frame>12 months</time_frame>
    <description>Adherence to PrEP using hair analysis measured by the concentration of antiretroviral drug in strands of hair.The results will be measured per participant using concentration in nanograms/milligrams.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will receive a behavioral intervention including counseling and offer of HIV oral fluid self test and PrEP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants will be not be offered HIV oral fluid self test but receive counseling, condoms and offered PrEP</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>POPPi behavioral intervention</intervention_name>
    <description>behavioral intervention with offer of HIV self test</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>POPPi behavioral intervention</intervention_name>
    <description>behavioral intervention</description>
    <arm_group_label>comparison</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female age 15- to 24-years old&#xD;
&#xD;
          -  Engaging in high-risk sexual behavior having had sex at least once in last three&#xD;
             months, --HlV-negative&#xD;
&#xD;
          -  Agree to participate in a minimum of four interviews over a 12-month period; including&#xD;
             baseline&#xD;
&#xD;
          -  Willing to receive services at Good Health for Women Project (GHWP)&#xD;
&#xD;
          -  For those initiating PrEP (Truvada):&#xD;
&#xD;
          -  Participants should have immunity to Hepatitis B infection and serum creatinine before&#xD;
&#xD;
          -  Contra-indications for starting Truvada to be considered include Creatinine &gt; 1.2 (&#xD;
             (mgldl) or 0.106 (mmolil) and a weight below 35kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to consent to participation in the study&#xD;
&#xD;
          -  Condition impeding participation in the study, including severe mental reason to the&#xD;
             discretion of the principal investigator, cognitive impairment or illness; serious&#xD;
             medical illness or developmental disability and any other reason to the discretion of&#xD;
             the principal investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel King, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uganda Virus Research Institute</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

